Re: ZEN-3694 Single Agent Trial Status
in response to
by
posted on
Sep 22, 2017 10:30AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
"The challenge is that it needs to be a $120,000,000 plus deal."
Toniv, please explain your $120,000,000 number. The Resverlogix loan is $68 million, right. Where are you coming up with the other $52 million? Is this for future operating costs of Resverlogix? Is this including Resverlogix AND Zenith debit together. Please explain.
BearDownAZ